Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P‐TIMI 50 trial
[...]in our trial-based analysis, despite a larger (~8-fold) gradient of HHF risk, patients with pre-existing heart failure actually had a lower cumulative HHF incidence in our study (3.8%/year) than was observed by Malik and colleagues among those with no HHF in the preceding 6 months (7.3%/year fo...
Gespeichert in:
| Veröffentlicht in: | Clinical cardiology (Mahwah, N.J.) N.J.), 2023-03, Vol.46 (3), p.348-349 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 349 |
|---|---|
| container_issue | 3 |
| container_start_page | 348 |
| container_title | Clinical cardiology (Mahwah, N.J.) |
| container_volume | 46 |
| creator | Freedman, Benjamin L. Berg, David D. Scirica, Benjamin M. Bohula, Erin A. Goodrich, Erica L. Sabatine, Marc S. Morrow, David A. Bonaca, Marc P. |
| description | [...]in our trial-based analysis, despite a larger (~8-fold) gradient of HHF risk, patients with pre-existing heart failure actually had a lower cumulative HHF incidence in our study (3.8%/year) than was observed by Malik and colleagues among those with no HHF in the preceding 6 months (7.3%/year for HFpEF; 9.7%/year for HFrEF). Since first and recurrent heart failure events are related, a total events analysis would be unlikely to produce a change of the magnitude needed to show a benefit. With regard to the use of antithrombotic therapy in patients with heart failure, the 2021 European Society of Cardiology (ESC) Guidelines cite a subgroup analysis of the COMPASS trial which showed that low-dose rivaroxaban has consistent benefit with respect to reducing MACE in patients with PAD and/or CAD and concomitant HFpEF or HFmrEF. 3 The statement relates to the consistent relative risk reduction for MACE in this subgroup, which owing to its high baseline risk, has a large absolute benefit. |
| doi_str_mv | 10.1002/clc.23972 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10018079</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2769376020</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4042-f684727e399f42dc2471c3a867e95ab2d6b2a3b99f26236c1cfe7a10bdff65533</originalsourceid><addsrcrecordid>eNp1kk9u1DAUhy1ERYfCggsgS2xgkaljZ-x4haoRf0aaClQN68hxnieuPHGwnVZlxRG4CBJn4CicpG6nVIDExl78Pn_v2c8IPSvJvCSEHmun55RJQR-gWSkZLWrBxEM0IyUnhaS1PESPYzzPKKkpe4QOGeeylJzM0PcziKMfIuDk8SlYDAkrN8cBtip0dtji1AO2g7YdDBqwGjo8BuisTj5E7A3ufRxtUs5-Ucn6ARsfcA8qJGyUdVPIZ3Y-e8Ycw5AivrSpxzGp1uUo24OP2t2sNuZCt_U2ZyeY_vzx8dfXb5vV6QovCE7BKvcEHRjlIjy924_Qp7dvNsv3xfrDu9XyZF3oilS0MLyuBBXApDQV7TStRKmZqrkAuVAt7XhLFWtzSjllXJfagFAlaTtj-GLB2BF6vfeOU7uDTue-g3LNGOxOhavGK9v8nQy2b7b-osnjKGsiZDa8vDME_3mCmJqdjRqcUwP4KTZUcMkEzxPJ6It_0HM_hSHfL1O1IJwTwTP1ak_p_FIxgLnvpiQ3ZWmTf0Fz-wsy-_zP9u_J32PPwPEeuLQOrv5vapbr5V55Deezv9Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2787066076</pqid></control><display><type>article</type><title>Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P‐TIMI 50 trial</title><source>MEDLINE</source><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Freedman, Benjamin L. ; Berg, David D. ; Scirica, Benjamin M. ; Bohula, Erin A. ; Goodrich, Erica L. ; Sabatine, Marc S. ; Morrow, David A. ; Bonaca, Marc P.</creator><creatorcontrib>Freedman, Benjamin L. ; Berg, David D. ; Scirica, Benjamin M. ; Bohula, Erin A. ; Goodrich, Erica L. ; Sabatine, Marc S. ; Morrow, David A. ; Bonaca, Marc P.</creatorcontrib><description>[...]in our trial-based analysis, despite a larger (~8-fold) gradient of HHF risk, patients with pre-existing heart failure actually had a lower cumulative HHF incidence in our study (3.8%/year) than was observed by Malik and colleagues among those with no HHF in the preceding 6 months (7.3%/year for HFpEF; 9.7%/year for HFrEF). Since first and recurrent heart failure events are related, a total events analysis would be unlikely to produce a change of the magnitude needed to show a benefit. With regard to the use of antithrombotic therapy in patients with heart failure, the 2021 European Society of Cardiology (ESC) Guidelines cite a subgroup analysis of the COMPASS trial which showed that low-dose rivaroxaban has consistent benefit with respect to reducing MACE in patients with PAD and/or CAD and concomitant HFpEF or HFmrEF. 3 The statement relates to the consistent relative risk reduction for MACE in this subgroup, which owing to its high baseline risk, has a large absolute benefit.</description><identifier>ISSN: 0160-9289</identifier><identifier>EISSN: 1932-8737</identifier><identifier>DOI: 10.1002/clc.23972</identifier><identifier>PMID: 36691960</identifier><language>eng</language><publisher>United States: John Wiley & Sons, Inc</publisher><subject>Atherosclerosis ; Atherosclerosis - epidemiology ; Cardiac arrhythmia ; Correspondence ; Heart failure ; Heart Failure - diagnosis ; Heart Failure - epidemiology ; Heart Failure - therapy ; Hospitalization ; Humans ; Incidence ; Myocardial Infarction - epidemiology</subject><ispartof>Clinical cardiology (Mahwah, N.J.), 2023-03, Vol.46 (3), p.348-349</ispartof><rights>2023 The Authors. published by Wiley Periodicals, LLC.</rights><rights>2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4042-f684727e399f42dc2471c3a867e95ab2d6b2a3b99f26236c1cfe7a10bdff65533</cites><orcidid>0000-0002-8533-0126</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018079/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018079/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36691960$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Freedman, Benjamin L.</creatorcontrib><creatorcontrib>Berg, David D.</creatorcontrib><creatorcontrib>Scirica, Benjamin M.</creatorcontrib><creatorcontrib>Bohula, Erin A.</creatorcontrib><creatorcontrib>Goodrich, Erica L.</creatorcontrib><creatorcontrib>Sabatine, Marc S.</creatorcontrib><creatorcontrib>Morrow, David A.</creatorcontrib><creatorcontrib>Bonaca, Marc P.</creatorcontrib><title>Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P‐TIMI 50 trial</title><title>Clinical cardiology (Mahwah, N.J.)</title><addtitle>Clin Cardiol</addtitle><description>[...]in our trial-based analysis, despite a larger (~8-fold) gradient of HHF risk, patients with pre-existing heart failure actually had a lower cumulative HHF incidence in our study (3.8%/year) than was observed by Malik and colleagues among those with no HHF in the preceding 6 months (7.3%/year for HFpEF; 9.7%/year for HFrEF). Since first and recurrent heart failure events are related, a total events analysis would be unlikely to produce a change of the magnitude needed to show a benefit. With regard to the use of antithrombotic therapy in patients with heart failure, the 2021 European Society of Cardiology (ESC) Guidelines cite a subgroup analysis of the COMPASS trial which showed that low-dose rivaroxaban has consistent benefit with respect to reducing MACE in patients with PAD and/or CAD and concomitant HFpEF or HFmrEF. 3 The statement relates to the consistent relative risk reduction for MACE in this subgroup, which owing to its high baseline risk, has a large absolute benefit.</description><subject>Atherosclerosis</subject><subject>Atherosclerosis - epidemiology</subject><subject>Cardiac arrhythmia</subject><subject>Correspondence</subject><subject>Heart failure</subject><subject>Heart Failure - diagnosis</subject><subject>Heart Failure - epidemiology</subject><subject>Heart Failure - therapy</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Incidence</subject><subject>Myocardial Infarction - epidemiology</subject><issn>0160-9289</issn><issn>1932-8737</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kk9u1DAUhy1ERYfCggsgS2xgkaljZ-x4haoRf0aaClQN68hxnieuPHGwnVZlxRG4CBJn4CicpG6nVIDExl78Pn_v2c8IPSvJvCSEHmun55RJQR-gWSkZLWrBxEM0IyUnhaS1PESPYzzPKKkpe4QOGeeylJzM0PcziKMfIuDk8SlYDAkrN8cBtip0dtji1AO2g7YdDBqwGjo8BuisTj5E7A3ufRxtUs5-Ucn6ARsfcA8qJGyUdVPIZ3Y-e8Ycw5AivrSpxzGp1uUo24OP2t2sNuZCt_U2ZyeY_vzx8dfXb5vV6QovCE7BKvcEHRjlIjy924_Qp7dvNsv3xfrDu9XyZF3oilS0MLyuBBXApDQV7TStRKmZqrkAuVAt7XhLFWtzSjllXJfagFAlaTtj-GLB2BF6vfeOU7uDTue-g3LNGOxOhavGK9v8nQy2b7b-osnjKGsiZDa8vDME_3mCmJqdjRqcUwP4KTZUcMkEzxPJ6It_0HM_hSHfL1O1IJwTwTP1ak_p_FIxgLnvpiQ3ZWmTf0Fz-wsy-_zP9u_J32PPwPEeuLQOrv5vapbr5V55Deezv9Q</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Freedman, Benjamin L.</creator><creator>Berg, David D.</creator><creator>Scirica, Benjamin M.</creator><creator>Bohula, Erin A.</creator><creator>Goodrich, Erica L.</creator><creator>Sabatine, Marc S.</creator><creator>Morrow, David A.</creator><creator>Bonaca, Marc P.</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8533-0126</orcidid></search><sort><creationdate>202303</creationdate><title>Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P‐TIMI 50 trial</title><author>Freedman, Benjamin L. ; Berg, David D. ; Scirica, Benjamin M. ; Bohula, Erin A. ; Goodrich, Erica L. ; Sabatine, Marc S. ; Morrow, David A. ; Bonaca, Marc P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4042-f684727e399f42dc2471c3a867e95ab2d6b2a3b99f26236c1cfe7a10bdff65533</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Atherosclerosis</topic><topic>Atherosclerosis - epidemiology</topic><topic>Cardiac arrhythmia</topic><topic>Correspondence</topic><topic>Heart failure</topic><topic>Heart Failure - diagnosis</topic><topic>Heart Failure - epidemiology</topic><topic>Heart Failure - therapy</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Incidence</topic><topic>Myocardial Infarction - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Freedman, Benjamin L.</creatorcontrib><creatorcontrib>Berg, David D.</creatorcontrib><creatorcontrib>Scirica, Benjamin M.</creatorcontrib><creatorcontrib>Bohula, Erin A.</creatorcontrib><creatorcontrib>Goodrich, Erica L.</creatorcontrib><creatorcontrib>Sabatine, Marc S.</creatorcontrib><creatorcontrib>Morrow, David A.</creatorcontrib><creatorcontrib>Bonaca, Marc P.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cardiology (Mahwah, N.J.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Freedman, Benjamin L.</au><au>Berg, David D.</au><au>Scirica, Benjamin M.</au><au>Bohula, Erin A.</au><au>Goodrich, Erica L.</au><au>Sabatine, Marc S.</au><au>Morrow, David A.</au><au>Bonaca, Marc P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P‐TIMI 50 trial</atitle><jtitle>Clinical cardiology (Mahwah, N.J.)</jtitle><addtitle>Clin Cardiol</addtitle><date>2023-03</date><risdate>2023</risdate><volume>46</volume><issue>3</issue><spage>348</spage><epage>349</epage><pages>348-349</pages><issn>0160-9289</issn><eissn>1932-8737</eissn><abstract>[...]in our trial-based analysis, despite a larger (~8-fold) gradient of HHF risk, patients with pre-existing heart failure actually had a lower cumulative HHF incidence in our study (3.8%/year) than was observed by Malik and colleagues among those with no HHF in the preceding 6 months (7.3%/year for HFpEF; 9.7%/year for HFrEF). Since first and recurrent heart failure events are related, a total events analysis would be unlikely to produce a change of the magnitude needed to show a benefit. With regard to the use of antithrombotic therapy in patients with heart failure, the 2021 European Society of Cardiology (ESC) Guidelines cite a subgroup analysis of the COMPASS trial which showed that low-dose rivaroxaban has consistent benefit with respect to reducing MACE in patients with PAD and/or CAD and concomitant HFpEF or HFmrEF. 3 The statement relates to the consistent relative risk reduction for MACE in this subgroup, which owing to its high baseline risk, has a large absolute benefit.</abstract><cop>United States</cop><pub>John Wiley & Sons, Inc</pub><pmid>36691960</pmid><doi>10.1002/clc.23972</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0002-8533-0126</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0160-9289 |
| ispartof | Clinical cardiology (Mahwah, N.J.), 2023-03, Vol.46 (3), p.348-349 |
| issn | 0160-9289 1932-8737 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10018079 |
| source | MEDLINE; Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Atherosclerosis Atherosclerosis - epidemiology Cardiac arrhythmia Correspondence Heart failure Heart Failure - diagnosis Heart Failure - epidemiology Heart Failure - therapy Hospitalization Humans Incidence Myocardial Infarction - epidemiology |
| title | Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P‐TIMI 50 trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T22%3A53%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response%20to%20Mei%20et%20al.%20regarding%20the%20incidence%20and%20predictors%20of%20hospitalization%20for%20heart%20failure%20among%20patients%20with%20stable%20atherosclerosis%20in%20the%20TRA%202%C2%B0P%E2%80%90TIMI%2050%20trial&rft.jtitle=Clinical%20cardiology%20(Mahwah,%20N.J.)&rft.au=Freedman,%20Benjamin%20L.&rft.date=2023-03&rft.volume=46&rft.issue=3&rft.spage=348&rft.epage=349&rft.pages=348-349&rft.issn=0160-9289&rft.eissn=1932-8737&rft_id=info:doi/10.1002/clc.23972&rft_dat=%3Cproquest_pubme%3E2769376020%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2787066076&rft_id=info:pmid/36691960&rfr_iscdi=true |